Isis off on mipomersen delay

Isis (NASDAQ:ISIS) fell $4.81 (29%) to $11.99 on Friday after it and partner Genzyme (NASDAQ:GENZ) announced delayed regulatory timelines for mipomersen. The partners

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE